Form 4 Filing for BioXcel Therapeutics, Inc. - Officer Transaction

This filing details transactions made by Javier Rodriguez, Chief Legal Officer, Senior Vice President and Corporate Secretary of BioXcel Therapeutics, Inc. On May 4, 2026, Rodriguez acquired 17,500 Restricted Stock Units (RSUs) with a reported value of $0.00, which represent contingent rights to receive an equal number of shares of the Issuer's Common Stock. The RSUs are subject to a vesting schedule, with 25% vesting six months after November 4, 2025, and the remainder vesting in three equal installments every six months thereafter, contingent upon continued employment. Additionally, on May 4, 2026, 17,500 shares of Common Stock were acquired, with a post-transaction share count of 33,363. On May 20, 2026, Rodriguez sold 6,560 shares of Common Stock at a weighted average price of $1.084 per share, ranging from $1.07 to $1.09. This sale was executed under a Rule 10b5-1 trading plan to cover taxes associated with the vesting of RSUs. Following this sale, Rodriguez holds 26,803 shares of Common Stock.